Q-omics provides the consensus-scored RELT profile across patient tissues and cancer cell-line models. RELT expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RELT is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RELT RNA expression shows 17,923 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where RELT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RELT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RELT survival associations across molecular data types. RELT RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RELT RNA expression–survival associations across cancer types. High RELT expression shows unfavorable associations in KIRC, ACC, UVM, KIRP, MESO and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RELT RNA expression.
This table summarizes RELT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RELT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RELT shows higher tumor expression in HNSC, KIRC, COAD, THCA, KIRP and UCEC. The HNSC box plot shows higher RELT RNA expression in tumor versus normal tissue (log2 FC = +1.449, t-test p < 0.001).
This table shows molecular features associated with RELT in patient tissues and cancer cell lines. In patient samples, RELT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RELT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
